ArticleKidney medicine2026
Humoral and Cellular Immune Responses Following Bivalent SARS-CoV-2 mRNA Vaccines in Patients Undergoing Hemodialysis: A Prospective Cohort Study.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Hemodialysis (HD) patients are susceptible to severe illness and mortality from coronavirus disease (COVID)-19. We investigated immunogenicity following bivalent vaccines containing ancestral and omicron variant (BA.1 or BA.4/BA.5) antigens in HD patients. Study Design: A prospective observational cohort study. Setting & Participants: We enrolled adult HD patients and age-matched healthy adults between October 2022 and February 2023. Blood samples were taken at baseline, 1 month (M1), and 3 months (M3) postvaccination. Exposures: Bivalent mRNA vaccines. Outcomes: Anti-SARS-CoV-2 spike protein receptor-binding domain antibodies, surrogate viral neutralization tests, pseudovirus neutralization tests, and SARS-CoV-2-specific interferon-γ release assay. Analytic Approach: Continuous variables were assessed using Results: Among 106 HD patients, 89.6% and 10.4% received either Spikevax Original/Omicron BA.1 or BA.4/5. Prior SARS-CoV-2 infection was documented in 25.5%, and 93.4% had received four monovalent vaccine doses. Anti-SARS-CoV-2-S antibody levels demonstrated a 4.2-fold increase at M1, subsequently declining by 50% at M3. Surrogate viral neutralization tests showed enhanced neutralization against Omicron BA.1, BA.2, and BA.4/5, with seropositive rates of 75.3% to 96% maintained at M3. Infection-naïve patients exhibited lower baseline antibodies but demonstrated more pronounced booster responses compared with previously infected individuals. Pseudovirus neutralization tests demonstrated 2-to-9.9-fold increases at M1 in neutralizing capacity against emerging Omicron subvariants BF.7, BA.2.75, BQ.1.1, and XBB.1.5. However, only 58.1% of patients demonstrated positive SARS-CoV-2-specific interferon-γ release assay responses at M1, with no correlation to humoral outcomes. Immune responses were comparable between HD patients and healthy controls. Limitations: Limited sample size, heterogeneous vaccination and infection history. Conclusions: Bivalent mRNA vaccines significantly enhanced antibody titers and broadened neutralizing capacity against emerging Omicron subvariants in HD patients. However, cellular immunity remained suboptimal despite multiple antigen exposures, highlighting the need for optimized vaccination strategies in this immunocompromised population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.